menu

Glioblastoma Treatment Market

Schedule Call

Glioblastoma Treatment Market

Glioblastoma Treatment Market by Treatment Type (Surgery, Radiation Therapy), Drug Class (Nitrosoureas, Anticonvulsants), End-user (Hospitals, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031

GR - 173813 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: March 13, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Glioblastoma Treatment Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 580 million

Revenue Forecast in 2031

US$ 1,235 million

CAGR

8.76%

Base Year for Estimation

2022

Forecast Period

2023-2031

Historical Year

2021

Segments Covered

Treatment Type, Drug Class, End-user, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global glioblastoma treatment market was valued at US$ 580 million in 2022 and is expected to register a revenue CAGR of 8.76% to reach US$ 1,235 million by 2031.

Glioblastoma Treatment Market Fundamentals

Glioblastoma is a type of malignant brain tumor that arises from astrocytes, which are star-shaped cells that support nerve cells in the brain. It is the most aggressive type of primary brain tumor, meaning it originates in the brain rather than spreading from another part of the body. It can quickly invade nearby tissues. The exact cause of glioblastoma is unknown, but it is believed to occur due to genetic mutations that result in uncontrolled growth and division of cells in the brain. Glioblastoma is more common in adults than children, affecting men more often than women. Symptoms of glioblastoma may include headaches, seizures, changes in mood or behavior, and problems with vision or speech.

Treatment for glioblastoma typically involves surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy. However, as glioblastoma cells can quickly multiply and spread, the prognosis for this type of tumor is often poor, with most patients surviving only 15 months to 2 years after diagnosis. Despite aggressive treatment, glioblastoma often recurs. Researchers are working to develop new treatments for glioblastoma, such as immunotherapy, which uses the body’s immune system to attack cancer cells. Clinical trials are also exploring targeted therapies that aim to block specific genetic mutations that drive the growth of glioblastoma cells.

[67568]

Glioblastoma Treatment Market Dynamics

The rising incidence of glioblastoma globally is the major growth driver of the global glioblastoma treatment market. For instance, according to the Brain Tumor Society, glioblastoma is one of the most complex, fatal, and resistant to the treatment of malignancies. In 2022, more than 13,000 people were expected to be diagnosed with glioblastoma. There is a growing pipeline of treatments for glioblastoma, including targeted therapies and immunotherapies. The new treatments have the potential to improve survival rates and quality of life for patients, which will fuel the revenue growth of the global glioblastoma treatment market. Additionally, advances in technology, such as precision medicine and genetic testing, are enabling researchers to understand the biology of glioblastoma better and develop more targeted treatments, which eventually results in the revenue growth of the global glioblastoma treatment market. Moreover, governments and healthcare organizations are investing more in the research and development of new treatments and improving patient care access, which will propel the global glioblastoma treatment market.

However, the cost of treating glioblastoma can be very high, particularly for newer immunotherapies and targeted therapies. This can be a barrier for patients who cannot afford these treatments and limit the market potential for these therapies. Moreover, despite advances in research, much is still not understood about the biology of glioblastoma. This can hinder the development of new treatments that effectively target the disease and hamper market revenue growth. Additionally, limited treatment options, regulatory challenges, and poor reimbursement policies in emerging nations are some restraints of the market revenue growth. 

 

Glioblastoma Treatment Market Ecosystem

The global glioblastoma treatment market is analyzed from four perspectives: treatment type, drug class, end-user, and region.

Glioblastoma Treatment Market by Treatment Type

[45765]

Based on the treatment type, the global glioblastoma treatment market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, and immunotherapy.

The radiation therapy segment dominated the market with the principal revenue share in 2022, attributed to improved survival rates. Radiation therapy offers high-energy radiation to kill cancer cells or slow their growth. It is a non-invasive treatment that does not require surgery or incisions. In glioblastoma treatment, radiation therapy can be delivered externally, using a linear accelerator to target the tumor from outside the body, or internally by placing radioactive material directly into the tumor bed. Radiation therapy can also shrink the size of the tumor, reducing pressure on the brain and relieving symptoms, such as headaches and seizures. This can make it a more attractive option for patients who may not be candidates for surgery. Radiation therapy is often combined with surgery and chemotherapy, allowing for a multi-modal approach to treating glioblastoma, thus resulting in better patient outcomes. Advances in radiation therapy techniques, such as intensity-modulated radiation therapy and proton therapy, have improved outcomes for patients with glioblastoma. These factors contribute to the revenue growth of the radiation therapy segment.

The targeted therapy segment is expected to be the fastest-growing segment throughout the forecast period, owing to the development of new drugs targeting these pathways. Targeted therapy is a treatment approach involving drugs that specifically target cancer cells while minimizing damage to healthy cells. Targeted therapy drugs for glioblastoma work by targeting specific molecular pathways involved in cancer cells’ growth and survival. These drugs can block the activity of proteins that promote cancer growth or stimulate the immune system to attack cancer cells. One example of a targeted therapy drug for glioblastoma is bevacizumab, which targets the protein VEGF (vascular endothelial growth factor) that stimulates the growth of new blood vessels in tumors. By blocking VEGF, bevacizumab can slow the growth of tumors and improve survival in some patients with glioblastoma. These factors contribute to the revenue growth of the targeted therapy segment.

Glioblastoma Treatment Market by Drug Class

Based on the drug class, the global glioblastoma treatment market is segmented into nitrosoureas, anticonvulsants, steroids, and other drugs. The other drugs segment includes drugs, such as bevacizumab and temozolomide. 

Bevacizumab is a targeted therapy drug that blocks the growth of blood vessels that supply the tumor. It has been approved by the U.S. Food and Drug Administration (FDA) for treating recurrent glioblastoma (rGBM) in adults. Bevacizumab is typically used with chemotherapy, such as temozolomide, to improve outcomes in patients with rGBM. The usage of bevacizumab in glioblastoma treatment has been controversial due to conflicting evidence on its efficacy and safety. While some studies have shown that it can improve progression-free survival and quality of life for patients with rGBM, others have not significantly improved survival rates. Temozolomide is an oral chemotherapy drug that is widely used in the treatment of glioblastoma. It is a prodrug converted into an active compound in the body, which then damages the DNA of cancer cells, preventing them from dividing and multiplying. Temozolomide is also used with radiation therapy as a first-line treatment for newly diagnosed glioblastoma. It has been shown to improve survival rates and delay disease progression in patients with this type of brain cancer, contributing to the growth of the other drugs segment.

Glioblastoma Treatment Market by End-user

Based on the end-user, the global glioblastoma treatment market is segmented into hospitals, ambulatory surgical centers, and others.

The hospitals segment dominated the global glioblastoma treatment market with the largest revenue share in 2022, as they are the primary setting for diagnosing and treating this disease. Hospitals have established multidisciplinary teams of neuro-oncology specialists, including neurosurgeons, radiation oncologists, medical oncologists, and neurologists. Hospitals provide various services for patients with glioblastoma, including surgery, radiation therapy, chemotherapy, and supportive care. In addition to providing treatment, hospitals also play a critical role in clinical trials of new therapies for glioblastoma. Clinical trials are essential for advancing the field of glioblastoma treatment and improving outcomes for patients. Hospitals also provide supportive care services for patients with glioblastoma, including pain management, nutrition counseling, and psychological support. Supportive care is an important aspect of glioblastoma treatment, as it can improve quality of life and help patients and their families cope with the challenges of this disease. These overall factors contribute to the growth of the hospital segment. 

Glioblastoma Treatment Market by Region

Geographically, the global glioblastoma treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominated the global glioblastoma treatment market with the largest revenue share in 2022, attributed to high awareness of rare disorders, easy access to high-quality medical care, and attractive reimbursement policies. Additionally, companies across the region are continuously involved in the research and development of novel drugs as well as treatments, which is also helping in the market revenue growth. For instance, in March 2023, SonALAsense, a pioneer in developing non-invasive Sonodynamic Treatment (SDT), employs SONALA-001 in conjunction with Insightec’s MR-guided focused ultrasound (MRgFUS), announced the completion of the first cohort in SDT-202. SDT-202 is an open-label, dose-escalation study of SDT in patients with rGBM. SDT-202, which expands on a prior proof-of-concept experiment at Barrow Neurological Institute, aims to assess the safety, appropriate dosage, and effectiveness of SDT.

Glioblastoma Treatment Market Competitive Landscape

The prominent players operating in the global glioblastoma treatment market are:

Glioblastoma Treatment Market Strategic Developments

  • In February 2023, Jubilant Therapeutics Inc. announced that the US FDA granted JBI-778 Orphan Drug Designation for treating Glioblastoma Multiforme. JBI-778 is an oral, brain penetrant, substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor used to treat malignancies with brain metastases and basic brain tumors, such as high-grade glioma. JBI-778 is an effective and specific inhibitor of PRMT5, which is overexpressed in many malignancies. JBI-778 is being developed to treat advanced tumors with certain genetic alterations and individuals with high-grade glioma with limited therapeutic options.
  • In July 2022, Diffusion Pharmaceuticals Inc. announced the Phase 2 clinical trial on TSC in newly diagnosed glioblastoma patients when administered with standard care therapies. The company anticipated starting the study by the end of 2022 and dosing the first patient in the first quarter of 2023. The study was expected to include a dose-escalation phase in which patients were supposed to be enrolled to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TSC at varied doses when administered in conjunction with standard-of-care radiotherapy plus temozolomide.

Frequently Asked Questions About This Report

Glioblastoma is a type of malignant brain tumor that arises from astrocytes, which are star-shaped cells that support nerve cells in the brain.

The global glioblastoma treatment market is expected to reach US$ 1,235 million by 2031.

The revenue CAGR of the glioblastoma treatment market will be 8.76% during the forecast period from 2023 to 2031.

The limited treatment options, regulatory challenges, and poor reimbursement policies in emerging nations restrict global market revenue growth to its full potential.

Some prominent players operating in the global glioblastoma treatment market are Accuray Inc., Brainlab AG, Bristol-Myers Squibb, Northwest Biotherapeutics, and AstraZeneca.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Products
      1. Secondary Products 
      2. Primary Products 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursements
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL GLIOBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Surgery
    2. Radiation Therapy
    3. Chemotherapy
    4. Targeted Therapy
    5. Tumor Treating Field (TTF) Therapy 
    6. Immunotherapy 
  6. GLOBAL GLIOBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Nitrosoureas
    2. Anticonvulsants
    3. Steroids
    4. Other Drugs
  7. GLOBAL GLIOBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY END-USER
    1. Hospitals
    2. Ambulatory Surgical Centers
    3. Others
  8. GLOBAL GLIOBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Glioblastoma Treatment Market
      1. North America Glioblastoma Treatment Market, by Treatment Type 
      2. North America Glioblastoma Treatment Market, by Drug Class
      3. North America Glioblastoma Treatment Market, by End-user
      4. North America Glioblastoma Treatment Market, by Country
        1. U.S.
          1. U.S. Glioblastoma Treatment Market, by Treatment Type 
          2. U.S. Glioblastoma Treatment Market, by Drug Class
          3. U.S. Glioblastoma Treatment Market, by End-user
        2. Canada
          1. Canada Glioblastoma Treatment Market, by Treatment Type 
          2. Canada Glioblastoma Treatment Market, by Drug Class
          3. Canada Glioblastoma Treatment Market, by End-user
    2. Europe Glioblastoma Treatment Market
      1. Europe Glioblastoma Treatment Market, by Treatment Type 
      2. Europe Glioblastoma Treatment Market, by Drug Class 
      3. Europe Glioblastoma Treatment Market, by End-user
      4. Europe Glioblastoma Treatment Market, by Country/Region
        1. Germany
          1. Germany Glioblastoma Treatment Market, by Treatment Type 
          2. Germany Glioblastoma Treatment Market, by Drug Class
          3. Germany Glioblastoma Treatment Market, by End-user 
        2. U.K.
          1. U.K. Glioblastoma Treatment Market, by Treatment Type 
          2. U.K. Glioblastoma Treatment Market, by Drug Class
          3. U.K. Glioblastoma Treatment Market, by End-user 
        3. France
          1. France Glioblastoma Treatment Market, by Treatment Type 
          2. France Glioblastoma Treatment Market, by Drug Class
          3. France Glioblastoma Treatment Market, by End-user
        4. Spain
          1. Spain Glioblastoma Treatment Market, by Treatment Type 
          2. Spain Glioblastoma Treatment Market, by Drug Class
          3. Spain Glioblastoma Treatment Market, by End-user 
        5. Italy
          1. Italy Glioblastoma Treatment Market, by Treatment Type 
          2. Italy Glioblastoma Treatment Market, by Drug Class
          3. Italy Glioblastoma Treatment Market, by End-user 
        6. Rest of Europe 
          1. Rest of Europe Glioblastoma Treatment Market, by Treatment Type 
          2. Rest of Europe Glioblastoma Treatment Market, by Drug Class
          3. Rest of Europe Glioblastoma Treatment Market, by End-user 
    3. Asia Pacific Glioblastoma Treatment Market
      1. Asia Pacific Glioblastoma Treatment Market, by Treatment Type 
      2. Asia Pacific Glioblastoma Treatment Market, by Drug Class
      3. Asia Pacific Glioblastoma Treatment Market, by End-user
      4. Asia Pacific Glioblastoma Treatment Market, by Country/Region
        1. China
          1. China Glioblastoma Treatment Market, by Treatment Type 
          2. China Glioblastoma Treatment Market, by Drug Class
          3. China Glioblastoma Treatment Market, by End-user 
        2. Japan
          1. Japan Glioblastoma Treatment Market, by Treatment Type 
          2. Japan Glioblastoma Treatment Market, by Drug Class 
          3. Japan Glioblastoma Treatment Market, by End-user
        3. India
          1. India Glioblastoma Treatment Market, by Treatment Type 
          2. India Glioblastoma Treatment Market, by Drug Class
          3. India Glioblastoma Treatment Market, by End-user 
        4. South Korea
          1. South Korea Glioblastoma Treatment Market, by Treatment Type 
          2. South Korea Glioblastoma Treatment Market, by Drug Class
          3. South Korea Glioblastoma Treatment Market, by End-user
        5. Australia
          1. Australia Glioblastoma Treatment Market, by Treatment Type 
          2. Australia Glioblastoma Treatment Market, by Drug Class
          3. Australia Glioblastoma Treatment Market, by End-user 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Glioblastoma Treatment Market, by Treatment Type 
          2. Rest of Asia Pacific Glioblastoma Treatment Market, by Drug Class
          3. Rest of Asia Pacific Glioblastoma Treatment Market, by End-user 
    4. Latin America Glioblastoma Treatment Market
      1. Latin America Glioblastoma Treatment Market, by Treatment Type 
      2. Latin America Glioblastoma Treatment Market, by Drug Class
      3. Latin America Glioblastoma Treatment Market, by End-user 
      4. Latin America Glioblastoma Treatment Market, by Country/ Region
        1. Brazil
          1. Brazil Glioblastoma Treatment Market, by Treatment Type 
          2. Brazil Glioblastoma Treatment Market, by Drug Class
          3. Brazil Glioblastoma Treatment Market, by End-user 
        2. Mexico
          1. Mexico Glioblastoma Treatment Market, by Treatment Type 
          2. Mexico Glioblastoma Treatment Market, by Drug Class 
          3. Mexico Glioblastoma Treatment Market, by End-user
        3. Argentina
          1. Argentina Glioblastoma Treatment Market, by Treatment Type 
          2. Argentina Glioblastoma Treatment Market, by Drug Class
          3. Argentina Glioblastoma Treatment Market, by End-user 
        4. Rest of Latin America
          1. Rest of Latin America Glioblastoma Treatment Market, by Treatment Type 
          2. Rest of Latin America Glioblastoma Treatment Market, by Drug Class 
          3. Rest of Latin America Glioblastoma Treatment Market, by End-user
    5. Middle East & Africa Glioblastoma Treatment Market
      1. Middle East & Africa Glioblastoma Treatment Market, by Treatment Type 
      2. Middle East & Africa Glioblastoma Treatment Market, by Drug Class
      3. Middle East & Africa Glioblastoma Treatment Market, by End-user 
      4. Middle East & Africa Glioblastoma Treatment Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Glioblastoma Treatment Market, by Treatment Type 
          2. GCC Countries Glioblastoma Treatment Market, by Drug Class
          3. GCC Countries Glioblastoma Treatment Market, by End-user 
        2. South Africa
          1. South Africa Glioblastoma Treatment Market, by Treatment Type 
          2. South Africa Glioblastoma Treatment Market, by Drug Class 
          3. South Africa Glioblastoma Treatment Market, by End-user
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Glioblastoma Treatment Market, by Treatment Type 
          2. Rest of Middle East & Africa Glioblastoma Treatment Market, by Drug Class
          3. Rest of Middle East & Africa Glioblastoma Treatment Market, by End-user 
  9. COMPANY PROFILES         
    1. Elekta
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Merck & Co.
    3. F. Hoffmann-La Roche Ltd.
    4. Pfizer Inc.
    5. Varian Medical Systems
    6. Sun Pharmaceutical Industries Ltd.
    7. Accuray Inc.
    8. Brainlab AG
    9. Bristol-Myers Squibb
    10. Northwest Biotherapeutics
    11. CarThera
    12. AstraZeneca

*Insights on financial performance are subject to the availability of information in the public domain

 

List of Tables

 

  1. Global Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million)
  2. Global Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  3. Global Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  4. Global Glioblastoma Treatment Market, by Region, 2021-2031 (US$ Million) 
  5. North America Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  6. North America Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  7. North America Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  8. North America Glioblastoma Treatment Market, by Country, 2021-2031 (US$ Million) 
  9. U.S. Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  10. U.S. Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  11. U.S. Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  12. Canada Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  13. Canada Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  14. Canada Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  15. Europe Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  16. Europe Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  17. Europe Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  18. Europe Glioblastoma Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  19. Germany Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  20. Germany Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  21. Germany Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million)
  22. U.K. Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  23. U.K. Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  24. U.K. Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million)
  25. France Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  26. France Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  27. France Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  28. Italy Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  29. Italy Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  30. Italy Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  31. Spain Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  32. Spain Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  33. Spain Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  34. Rest of Europe Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  35. Rest of Europe Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  36. Rest of Europe Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  37. Asia Pacific Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  38. Asia Pacific Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  39. Asia Pacific Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  40. Asia Pacific Glioblastoma Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  41. China Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  42. China Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  43. China Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  44. Japan Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  45. Japan Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  46. Japan Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  47. India Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  48. India Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  49. India Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  50. South Korea Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  51. South Korea Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  52. South Korea Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  53. Australia Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  54. Australia Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  55. Australia Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  56. Rest of Asia Pacific Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  58. Rest of Asia Pacific Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million)
  59. Latin America Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  60. Latin America Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  61. Latin America Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  62. Latin America Glioblastoma Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  63. Brazil Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  64. Brazil Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  65. Brazil Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  66. Mexico Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  67. Mexico Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  68. Mexico Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  69. Argentina Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  70. Argentina Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  71. Argentina Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  72. Rest of Latin America Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  73. Rest of Latin America Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  74. Rest of Latin America Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million)
  75. Middle East and Africa Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  76. Middle East and Africa Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  77. Middle East and Africa Glioblastoma Treatment Market, by End-user 2021–2031 (US$ Million)
  78. Middle East and Africa Glioblastoma Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  79. GCC Countries Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  80. GCC Countries Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  81. GCC Countries Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  82. South Africa Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  83. South Africa Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  84. South Africa Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million) 
  85. Rest of Middle East & Africa Glioblastoma Treatment Market, by Treatment Type, 2021-2031 (US$ Million) 
  86. Rest of Middle East & Africa Glioblastoma Treatment Market, by Drug Class, 2021–2031 (US$ Million) 
  87. Rest of Middle East & Africa Glioblastoma Treatment Market, by End-user, 2021–2031 (US$ Million)

List of Figures

 

  1. Glioblastoma Treatment Market Ecosystem  
  2. Snapshot of Global Glioblastoma Treatment Market, 2021-2031 
  3. Snapshot of Global Glioblastoma Treatment Market, by Region, 2021-2031 
  4. Global Glioblastoma Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Glioblastoma Treatment Market: Key Players & Competitive Positioning (2022) 
  6. Glioblastoma Treatment: Market Dynamics 
  7. Global Glioblastoma Treatment Market for Surgery, 2021-2031 (US$ Million) 
  8. Global Glioblastoma Treatment Market for Radiation Therapy, 2021-2031 (US$ Million) 
  9. Global Glioblastoma Treatment Market for Chemotherapy, 2021-2031 (US$ Million) 
  10. Global Glioblastoma Treatment Market for Targeted Therapy, 2021-2031 (US$ Million)
  11. Global Glioblastoma Treatment Market for Tumor Treating Field (TTF) Therapy 2021-2031 (US$ Million)
  12. Global Glioblastoma Treatment Market for Immunotherapy, 2021-2031 (US$ Million)
  13. Global Glioblastoma Treatment Market for Nitrosoureas, 2021-2031 (US$ Million)
  14. Global Glioblastoma Treatment Market for Anticonvulsants, 2021-2031 (US$ Million)
  15. Global Glioblastoma Treatment Market for Steroids, 2021-2031 (US$ Million)
  16. Global Glioblastoma Treatment Market for Other Drugs, 2021-2031 (US$ Million)
  17. Global Glioblastoma Treatment Market for Hospitals, 2021-2031 (US$ Million)
  18. Global Glioblastoma Treatment Market for Ambulatory Surgical Centers, 2021-2031 (US$ Million)
  19. Global Glioblastoma Treatment Market for Others, 2021-2031 (US$ Million)
  20. North America Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  21. U.S. Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  22. Canada Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  23. Europe Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  24. Germany Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  25. U.K. Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  26. France Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  27. Italy Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  28. Spain Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  29. Rest of Europe Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  30. Asia Pacific Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  31. China Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  32. Japan Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  33. India Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  34. South Korea Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  35. Australia Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  36. Rest of Asia Pacific Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  37. Latin America Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  38. Brazil Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  39. Mexico Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  40. Argentina Glioblastoma Treatment Market, 2021-2031 (US$ Million)
  41. Rest of Latin America Glioblastoma Treatment Market, 2021-2031 (US$ Million)
  42. Middle East & Africa Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  43. GCC Countries Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  44. South Africa Glioblastoma Treatment Market, 2021-2031 (US$ Million) 
  45. Rest of Middle East & Africa Glioblastoma Treatment Market, 2021-2031 (US$ Million)
  46. Elekta Revenue from 2019 Onwards (US$ Million)
  47. Merck & Co Revenue from 2019 Onwards (US$ Million)
  48. F. Hoffmann-La Roche Ltd. Revenue from 2019 Onwards (US$ Million)
  49. Pfizer Inc. Revenue from 2019 Onwards (US$ Million)
  50. Varian Medical Systems Revenue from 2019 Onwards (US$ Million)
  51. Sun Pharmaceutical Industries Ltd. Revenue from 2019 Onwards (US$ Million)
  52. Accuray Inc. Revenue from 2019 Onwards (US$ Million)
  53. Brainlab AG Revenue from 2019 Onwards (US$ Million)
  54. Bristol-Myers Squibb Revenue from 2019 Onwards (US$ Million)
  55. Northwest Biotherapeutics Revenue from 2019 Onwards (US$ Million)
  56. CarThera Revenue from 2019 Onwards (US$ Million)
  57. AstraZeneca Revenue from 2019 Onwards (US$ Million)

Frequently Asked Questions About This Report

 

 

 

 

 

 

 

 

 

 


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Glioblastoma Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Glioblastoma Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports